349 related articles for article (PubMed ID: 27608656)
1. Identification and Characterization of New Chemical Entities Targeting Apurinic/Apyrimidinic Endonuclease 1 for the Prevention of Chemotherapy-Induced Peripheral Neuropathy.
Kelley MR; Wikel JH; Guo C; Pollok KE; Bailey BJ; Wireman R; Fishel ML; Vasko MR
J Pharmacol Exp Ther; 2016 Nov; 359(2):300-309. PubMed ID: 27608656
[TBL] [Abstract][Full Text] [Related]
2. Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy.
Kelley MR; Jiang Y; Guo C; Reed A; Meng H; Vasko MR
PLoS One; 2014; 9(9):e106485. PubMed ID: 25188410
[TBL] [Abstract][Full Text] [Related]
3. Small molecule activation of apurinic/apyrimidinic endonuclease 1 reduces DNA damage induced by cisplatin in cultured sensory neurons.
Georgiadis MM; Chen Q; Meng J; Guo C; Wireman R; Reed A; Vasko MR; Kelley MR
DNA Repair (Amst); 2016 May; 41():32-41. PubMed ID: 27078577
[TBL] [Abstract][Full Text] [Related]
4. APE1, the DNA base excision repair protein, regulates the removal of platinum adducts in sensory neuronal cultures by NER.
Kim HS; Guo C; Thompson EL; Jiang Y; Kelley MR; Vasko MR; Lee SH
Mutat Res; 2015 Sep; 779():96-104. PubMed ID: 26164266
[TBL] [Abstract][Full Text] [Related]
5. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons.
Jiang Y; Guo C; Vasko MR; Kelley MR
Cancer Res; 2008 Aug; 68(15):6425-34. PubMed ID: 18676868
[TBL] [Abstract][Full Text] [Related]
6. Oxidative DNA Damage and Cisplatin Neurotoxicity Is Exacerbated by Inhibition of OGG1 Glycosylase Activity and APE1 Endonuclease Activity in Sensory Neurons.
Behrouzi A; Xia H; Thompson EL; Kelley MR; Fehrenbacher JC
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163831
[TBL] [Abstract][Full Text] [Related]
7. The repair function of the multifunctional DNA repair/redox protein APE1 is neuroprotective after ionizing radiation.
Vasko MR; Guo C; Thompson EL; Kelley MR
DNA Repair (Amst); 2011 Sep; 10(9):942-52. PubMed ID: 21741887
[TBL] [Abstract][Full Text] [Related]
8. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
9. DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA repair function of APE1.
Fehrenbacher JC; Guo C; Kelley MR; Vasko MR
Neuroscience; 2017 Dec; 366():23-35. PubMed ID: 28965839
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors.
Zawahir Z; Dayam R; Deng J; Pereira C; Neamati N
J Med Chem; 2009 Jan; 52(1):20-32. PubMed ID: 19072053
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone.
Luo M; Kelley MR
Anticancer Res; 2004; 24(4):2127-34. PubMed ID: 15330152
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of apurinic/apyrimidinic endonuclease I's redox activity revisited.
Zhang J; Luo M; Marasco D; Logsdon D; LaFavers KA; Chen Q; Reed A; Kelley MR; Gross ML; Georgiadis MM
Biochemistry; 2013 Apr; 52(17):2955-66. PubMed ID: 23597102
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of novel analogues of E3330 that block the redox signaling activity of the multifunctional AP endonuclease/redox signaling enzyme APE1/Ref-1.
Kelley MR; Luo M; Reed A; Su D; Delaplane S; Borch RF; Nyland RL; Gross ML; Georgiadis MM
Antioxid Redox Signal; 2011 Apr; 14(8):1387-401. PubMed ID: 20874257
[TBL] [Abstract][Full Text] [Related]
14. Ref-1/APE1 Inhibition with Novel Small Molecules Blocks Ocular Neovascularization.
Sardar Pasha SPB; Sishtla K; Sulaiman RS; Park B; Shetty T; Shah F; Fishel ML; Wikel JH; Kelley MR; Corson TW
J Pharmacol Exp Ther; 2018 Oct; 367(1):108-118. PubMed ID: 30076264
[TBL] [Abstract][Full Text] [Related]
15. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
Amara S
Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
[TBL] [Abstract][Full Text] [Related]
16. Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy.
Bakogeorgos M; Georgoulias V
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1045-1060. PubMed ID: 28868935
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
Ewertz M; Qvortrup C; Eckhoff L
Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757
[TBL] [Abstract][Full Text] [Related]
18. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.
Gewandter JS; Brell J; Cavaletti G; Dougherty PM; Evans S; Howie L; McDermott MP; O'Mara A; Smith AG; Dastros-Pitei D; Gauthier LR; Haroutounian S; Jarpe M; Katz NP; Loprinzi C; Richardson P; Lavoie-Smith EM; Wen PY; Turk DC; Dworkin RH; Freeman R
Neurology; 2018 Aug; 91(9):403-413. PubMed ID: 30054438
[TBL] [Abstract][Full Text] [Related]
19. Roles of Transient Receptor Potential Ankyrin 1 in Oxaliplatin-Induced Peripheral Neuropathy.
Nakagawa T; Kaneko S
Biol Pharm Bull; 2017; 40(7):947-953. PubMed ID: 28674258
[TBL] [Abstract][Full Text] [Related]
20. Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: an in vitro study.
Maggioni D; Nicolini G; Chiorazzi A; Meregalli C; Cavaletti G; Tredici G
J Neurosci Res; 2010 Nov; 88(14):3171-9. PubMed ID: 20722073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
